CA-CROWN-BIOSCIENCE
7.10.2021 14:32:07 CEST | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company and leader in translational services that help biopharmaceutical companies accelerate new drug development programs, today announced the launch of its ‘3D Ex Vivo Patient Tissue Platform’. Using freshly collected patient tumor material, this new service can accurately measure oncology and immuno-oncology drug-induced tumor killing and endogenous immune cell proliferation in a high throughput format. Researchers are presenting data on the new platform at this year’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , which is happening virtually on October 7-10, 2021.
The proprietary technology, developed at Crown Bioscience’s recently acquired site in Leiden, The Netherlands (formerly known as OcellO B.V.), aims to improve clinical success rates by using the most patient-relevant tumor samples to better predict tumor response to potential drug candidates.
“Our goal is to leverage our core technologies to build a translational model system that adequately captures the tumor architecture and microenvironment, and improves the predictability of patient responses to treatment protocols for existing and potential therapeutic candidates,” said Leo Price, PhD, Senior Vice President, In Vitro . “We believe this approach provides greater translational relevance in drug development by using immuno-competent primary human tumor tissue to help analyze drug candidate responses before the program enters clinical trial. This approach is an optimal fit with our mission to help deliver the right drug to the right patient at the right time.”
The ‘3D Ex Vivo Patient Tissue Platform’ utilizes patient tumor tissue isolated from biopsies, surgical resections, ascites, or pleural effusion samples that are processed within 24 hours to preserve the tumor microenvironment. The automated high throughput platform uses high content 3D imaging and image analysis to quantify distinct responses of individual cell populations in fresh patient tissues. These analyses can assess responses to different doses of therapeutic candidates at various timepoints and can determine the effects of the drug or combination of drugs on tumor killing and immune cell proliferation.
“We believe this new service can help fill a critical gap in today’s research landscape with early translational patient-relevant ex vivo models that can assess efficacy and determine mechanisms of action,” commented Armin Spura, PhD, Chief Executive Officer of Crown Bioscience . “This new service offering is designed to help mitigate the high failure rates of clinical programs in oncology, and was one of the objectives coming out of our recent OcellO acquisition. We are delighted to provide immediate value to our customers from this investment and look forward to the future value that this acquisition will bring.”
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Researchers from CrownBio are conducting a poster presentation titled, “Novel Near Vivo Drug Response Platform for Oncology using 3D Ex Vivo Patient-Derived Microtumors” at the annual conference. The poster summarizes:
- This 3D high content assay on ex vivo patient tumor material preserves native tumor microenvironement and architecture
- Ex vivo testing using ultra fresh patient tumor samples maintains intact endogenous immune cell populations
- Ongoing clinical trial collaborations with tissue providers for ovarian cancer, bladder cancer, NSCLC, and other tumor samples
For more information on Crown Bioscience’s 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscienes's webpage on the new service.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, immuno-oncology, and immune mediated inflammatory disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Convatec’s Advanced Wound Care Innovation Leads the Industry at European Wound Management Association (EWMA) 20265.5.2026 16:11:00 CEST | Press release
Convatec will showcase new clinical and real‑world evidence across next‑generation foam technology, nitric oxide‑generating dressings, and Wound HygieneConvatec-sponsored scientific symposia to spotlight patient-centred innovation supported by robust in-vitro and clinical data enabling HCPs to deliver better outcomesConvatec to unveil Aquacel™ ConvaFiber™ in its European debut ahead of scale-up later this year Convatec, a leading medical products and technology company focused on chronic condition management, takes to the stage to showcase the breadth, depth and momentum behind its Advanced Wound Care innovation pipeline at the European Wound Management Association (EWMA) 2026 conference in Bremen, Germany, from 6–8 May 2026. Convatec’s industry-leading Advanced Wound Care innovation is supported by compelling new data from randomised controlled trials (RCTs) and real-world studies, with 13 abstracts accepted for publication and presentation at EWMA evaluating outcomes in hard-to-heal
Laserfiche Recognized as a Leader in 2026 Gartner® Magic Quadrant™ for Document Management5.5.2026 16:00:00 CEST | Press release
Laserfiche named a Leader for the second consecutive time based on its Completeness of Vision and Ability to Execute Laserfiche — the leading SaaS provider of intelligent content management — has been positioned as a Leader in the 2026 Magic Quadrant for Document Management. Laserfiche believes this recognition underscores the company’s commitment to empowering organizations to transform complex, operational business processes through AI-powered content management. “It’s incredible to see Laserfiche recognized during the same week as our annual Empower conference, where we announced our latest agentic AI capabilities,” said Thomas Phelps, senior vice president of corporate strategy and chief information officer at Laserfiche. “We believe being positioned as a Leader — and receiving the highest overall rating among 16 vendors in Gartner Peer Insights, with a 4.7 out of 5.0 based on over 1,300 reviews as of April 30, 2026 — reflects our relentless focus on product innovation and deliveri
De’ Longhi and La Marzocco Redefine the Coffee Experience at Milan Design Week 20265.5.2026 15:43:00 CEST | Press release
In the heart of Brera, Milan’s most iconic neighbourhood, the Group celebrated coffee, design, and innovation with two immersive spaces: CASA La Marzocco and The Smallest Coffee Shop at Home with De’ Longhi Milan Design Week annually transforms the city into a global stage for design culture and functional aesthetics, attracting hundreds of thousands of visitors and creatives from around the world to define the year's leading trends. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505367702/en/ Once again, the De’ Longhi Group took the spotlight with activations dedicated to the evolving world of coffee, spanning at-home rituals and out-of-home professional settings. For Milan Design Week 2026, De’ Longhi presented 'The Smallest Coffee Shop at Home,' where the brand reimagined its bestselling machines in the style of cafes around the world. The idea was developed in collaboration with master miniaturist Simon Weisse. The v
Submission Deadline for 5th Cycle of the Mohammed bin Rashid Al Maktoum Global Water Award Extended to 30 September 20265.5.2026 15:41:00 CEST | Press release
In response to requests from a large number of participants, the UAE Water Aid Foundation (Suqia UAE) has extended the submission deadline for the fifth cycle of the Mohammed bin Rashid Al Maktoum Global Water Award to 30 September 2026. The extension aims to enable the widest possible participation from applicants around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505894901/en/ Submission deadline for 5th cycle of the Mohammed bin Rashid Al Maktoum Global Water Award extended to 30 September 2026 (Photo: AETOSWire) Launched by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and overseen by Suqia UAE under the umbrella of the Mohammed bin Rashid Al Maktoum Global Initiatives, the award supports research and development efforts to develop sustainable solutions to address the global water crisis using renewable energy. It aims to tackle water scarcity
LTM and Uniphore Partner to Scale Domain-Specific AI Across Core Business Processes5.5.2026 15:15:00 CEST | Press release
Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem to deliver industry-specific small language models and AI agents for core enterprise workflows Uniphore, the Business AI Company, and LTM, the Business Creativity partner to the world's largest enterprises, today announced a strategic partnership focused on the joint development of industry- and domain-specific AI solutions that combine small language models (SLMs), AI agents, and deep domain expertise. As AI adoption matures, enterprises are shifting to smaller, purpose‑built models and agents for greater precision and control. The partnership brings this approach to core business processes with governance, security, and compliance by design. Uniphore’s Business AI Cloud will power LTM’s BlueVerse™ ecosystem and global delivery, unifying enterprise data, models, and AI agents on a secure, sovereign platform. LTM will drive industry expertise, client implementation, and AI‑led transformation, while Uniphore provides the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom